Ningxia Zhongke Biotechnology Co Ltd

Ningxia Zhongke Biotechnology Co Ltd has a market capitalization of 4.8 billion CNY and a price-to-book ratio of 3.97, indicating that the market values the company at nearly four times its book value. The company's liquidity position is characterized as medium, with a current ratio of 2.77, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at -373.4 million CNY, and its free cash flow is also negative at -310.0 million CNY, indicating that the company is not generating positive cash from its operations.

The company's profitability is weak, with a net loss of 90.4 million CNY and a return on equity of -7.48%, which is significantly below the industry median for commodity chemicals. The company's return on assets is also negative at -3.63%, further highlighting its poor performance in generating returns from its asset base. The company's gross profit is negative at -200.3 million CNY, and its operating income is also negative at -137.4 million CNY, indicating that the company is not able to cover its operating costs.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. The company's revenue for the latest period is 444.5 million CNY, and there is no indication of significant revenue growth in the near term. The company's capital expenditure for the period is -271.2 million CNY, indicating that the company is investing in its operations, but the negative value suggests that the investment is not yet generating positive returns.

The company's outlook for the current fiscal year is negative, with a net loss expected to continue. The company's debt-to-equity ratio is 0.72, indicating that the company has a moderate level of debt relative to its equity. The company's liquidity risk is medium, and its credit risk is not explicitly stated, but the negative operating cash flow and free cash flow suggest that the company may face challenges in meeting its financial obligations. The company's dilution risk is low, and there is no indication of significant dilution in the near term.

Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's recent financial performance is consistent with its historical performance, with no significant improvements or deteriorations noted. The company's risk assessment indicates that it has a medium liquidity risk and a low dilution risk, but the negative operating cash flow and free cash flow suggest that the company may need to seek additional financing in the near term.